Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX) had its price objective upped by Robert W. Baird from $16.00 to $17.00 in a research note issued to investors on Friday. Robert W. Baird currently has an outperform rating on the software maker’s stock.

MDRX has been the subject of a number of other research reports. Jefferies Group LLC set a $17.00 price objective on Allscripts Healthcare Solutions and gave the company a buy rating in a research note on Friday, August 25th. Cantor Fitzgerald reissued a buy rating and issued a $17.00 price objective on shares of Allscripts Healthcare Solutions in a research note on Wednesday, September 27th. Zacks Investment Research cut Allscripts Healthcare Solutions from a hold rating to a sell rating in a research note on Tuesday, October 10th. Maxim Group reissued a buy rating and issued a $16.00 price objective on shares of Allscripts Healthcare Solutions in a research note on Friday, August 4th. Finally, Dougherty & Co reissued a buy rating and issued a $16.00 price objective (up previously from $15.00) on shares of Allscripts Healthcare Solutions in a research note on Tuesday, October 3rd. Two analysts have rated the stock with a sell rating, eight have issued a hold rating and eleven have given a buy rating to the company’s stock. The company has an average rating of Hold and a consensus price target of $15.13.

Allscripts Healthcare Solutions (NASDAQ:MDRX) traded up $0.19 during midday trading on Friday, reaching $12.94. The company had a trading volume of 3,153,506 shares, compared to its average volume of 1,746,091. Allscripts Healthcare Solutions has a fifty-two week low of $9.80 and a fifty-two week high of $14.45. The firm has a market capitalization of $2,337.12, a PE ratio of 30.09, a P/E/G ratio of 2.42 and a beta of 1.35. The company has a quick ratio of 0.93, a current ratio of 0.93 and a debt-to-equity ratio of 1.13.

Allscripts Healthcare Solutions (NASDAQ:MDRX) last announced its quarterly earnings data on Thursday, August 3rd. The software maker reported $0.11 EPS for the quarter, missing the Zacks’ consensus estimate of $0.15 by ($0.04). Allscripts Healthcare Solutions had a negative net margin of 12.23% and a positive return on equity of 6.44%. The firm had revenue of $426.10 million during the quarter, compared to analyst estimates of $424.94 million. During the same period last year, the business posted $0.14 EPS. The company’s revenue was up 10.2% on a year-over-year basis. sell-side analysts predict that Allscripts Healthcare Solutions will post 0.45 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: This report was first reported by Watch List News and is owned by of Watch List News. If you are viewing this report on another domain, it was copied illegally and reposted in violation of United States & international trademark and copyright laws. The legal version of this report can be accessed at https://www.watchlistnews.com/allscripts-healthcare-solutions-inc-mdrx-price-target-increased-to-17-00-by-analysts-at-robert-w-baird/1681488.html.

In other news, President Richard J. Poulton sold 15,000 shares of Allscripts Healthcare Solutions stock in a transaction on Friday, September 15th. The stock was sold at an average price of $13.56, for a total value of $203,400.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Brian Farley sold 5,000 shares of Allscripts Healthcare Solutions stock in a transaction on Thursday, September 14th. The shares were sold at an average price of $13.52, for a total value of $67,600.00. Following the completion of the transaction, the executive vice president now owns 196,607 shares of the company’s stock, valued at $2,658,126.64. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 35,000 shares of company stock worth $473,800. Corporate insiders own 0.75% of the company’s stock.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Archford Capital Strategies LLC grew its position in Allscripts Healthcare Solutions by 6,124.0% during the second quarter. Archford Capital Strategies LLC now owns 6,224 shares of the software maker’s stock worth $958,000 after buying an additional 6,124 shares in the last quarter. Virtu Financial LLC purchased a new position in Allscripts Healthcare Solutions during the second quarter worth about $134,000. Bank of Montreal Can grew its position in Allscripts Healthcare Solutions by 6.9% during the second quarter. Bank of Montreal Can now owns 10,603 shares of the software maker’s stock worth $135,000 after buying an additional 689 shares in the last quarter. World Asset Management Inc grew its position in Allscripts Healthcare Solutions by 0.7% during the second quarter. World Asset Management Inc now owns 11,419 shares of the software maker’s stock worth $146,000 after buying an additional 81 shares in the last quarter. Finally, ETF Managers Group LLC purchased a new position in Allscripts Healthcare Solutions during the second quarter worth about $152,000.

Allscripts Healthcare Solutions Company Profile

Allscripts Healthcare Solutions, Inc (Allscripts) delivers information technology (IT) solutions and services to help healthcare organizations. The Company operates through three segments: Clinical and Financial Solutions, Population Health, and Netsmart. The Clinical and Financial Solutions segment includes the sale of integrated clinical software applications and financial and information solutions.

Analyst Recommendations for Allscripts Healthcare Solutions (NASDAQ:MDRX)

Receive News & Ratings for Allscripts Healthcare Solutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allscripts Healthcare Solutions Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.